<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, May 7, 2020 (HealthDay News) — A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori<\/i>, with eradication rates unaffected by resistance to clarithromycin or metronidazole, according to a study published online May 5 in the Annals of Internal Medicine<\/i>.<\/p>\n
David Y. Graham, M.D., from the Baylor College of Medicine in Houston, and colleagues examined the effectiveness of RHB-105 for eradication of H. pylori<\/i> in a phase 3 double-blind trial conducted at 55 clinical research sites in the United States. A total of 455 treatment-naive adults were randomly assigned to receive either RHB-105 (amoxicillin, omeprazole, and rifabutin) or active comparator (amoxicillin and omeprazole).<\/p>\n
The researchers found that the eradication rate was significantly higher with RHB-105 than with the active comparator (83.8 versus 57.7 percent) in the intention-to-treat analysis. Resistance to clarithromycin or metronidazole did not affect eradication rates. There was no detection of rifabutin resistance. Diarrhea (10.1 percent with RHB-105 versus 7.9 percent with the active comparator), headache (7.5 versus 7.0 percent), and nausea (4.8 versus 5.3 percent) were the most commonly reported adverse events.<\/p>\n
“A new treatment option will help address the unmet need of providing effective, well-tolerated therapy in an environment of clinically significant antibiotic resistance,” the authors write.<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical industry, including RedHill Biopharma, which funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n